Marinus Pharmaceuticals, Inc. updated revenue guidance for the fiscal year 2023. For the year, the Company now expects ZTALMY net product revenues of between $18.5 and $19 million; this represents an increase from the previous guidance of between $17 and $18.5 million.
Market Closed -
Other stock markets
|
Pre-market 07:00:02 am | |||
1.405 USD | -1.06% | 1.41 | +0.36% |
Apr. 17 | Truist Adjusts Marinus Pharmaceuticals' PT to $10 From $25, Keeps Buy Rating | MT |
Apr. 16 | Baird Downgrades Marinus Pharmaceuticals to Neutral, Price Target at $2 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-87.07% | 77.17M | |
+25.83% | 661B | |
+26.64% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+14.81% | 231B | |
+5.31% | 200B | |
-8.79% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- MRNS Stock
- News Marinus Pharmaceuticals, Inc.
- Marinus Pharmaceuticals, Inc. Updates Revenue Guidance for the Fiscal Year 2023